123 related articles for article (PubMed ID: 30498096)
1. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.
Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE
Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096
[TBL] [Abstract][Full Text] [Related]
2. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract][Full Text] [Related]
3. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.
Mochizuki D; Adams A; Warner KA; Zhang Z; Pearson AT; Misawa K; McLean SA; Wolf GT; Nör JE
Oncotarget; 2015 Sep; 6(26):22822-35. PubMed ID: 26287605
[TBL] [Abstract][Full Text] [Related]
5. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.
Yi H; Yan X; Luo Q; Yuan L; Li B; Pan W; Zhang L; Chen H; Wang J; Zhang Y; Zhai Y; Qiu MZ; Yang DJ
J Exp Clin Cancer Res; 2018 May; 37(1):97. PubMed ID: 29716622
[TBL] [Abstract][Full Text] [Related]
7. Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy.
Cheng J; Yan Z; Jiang K; Liu C; Xu D; Lyu X; Hu X; Zhang S; Zhou Y; Li J; Zhao Y
J Med Chem; 2023 Dec; 66(24):16991-17025. PubMed ID: 38062557
[TBL] [Abstract][Full Text] [Related]
8. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
[TBL] [Abstract][Full Text] [Related]
9. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.
Wienken M; Dickmanns A; Nemajerova A; Kramer D; Najafova Z; Weiss M; Karpiuk O; Kassem M; Zhang Y; Lozano G; Johnsen SA; Moll UM; Zhang X; Dobbelstein M
Mol Cell; 2016 Jan; 61(1):68-83. PubMed ID: 26748827
[TBL] [Abstract][Full Text] [Related]
10. p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors.
Li WF; Alfason L; Huang C; Tang Y; Qiu L; Miyagishi M; Wu SR; Kasim V
Acta Pharmacol Sin; 2023 Mar; 44(3):647-660. PubMed ID: 35995868
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
Chessari G; Hardcastle IR; Ahn JS; Anil B; Anscombe E; Bawn RH; Bevan LD; Blackburn TJ; Buck I; Cano C; Carbain B; Castro J; Cons B; Cully SJ; Endicott JA; Fazal L; Golding BT; Griffin RJ; Haggerty K; Harnor SJ; Hearn K; Hobson S; Holvey RS; Howard S; Jennings CE; Johnson CN; Lunec J; Miller DC; Newell DR; Noble MEM; Reeks J; Revill CH; Riedinger C; St Denis JD; Tamanini E; Thomas H; Thompson NT; Vinković M; Wedge SR; Williams PA; Wilsher NE; Zhang B; Zhao Y
J Med Chem; 2021 Apr; 64(7):4071-4088. PubMed ID: 33761253
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction.
Lin Z; Liu C; Yan Z; Cheng J; Wang X; Zhou F; Lyu X; Zhang S; Zhang D; Meng X; Zhao Y
Eur J Med Chem; 2024 Apr; 270():116366. PubMed ID: 38581730
[TBL] [Abstract][Full Text] [Related]
13. MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production.
Langenbach M; Giesler S; Richtsfeld S; Costa-Pereira S; Rindlisbacher L; Wertheimer T; Braun LM; Andrieux G; Duquesne S; Pfeifer D; Woessner NM; Menssen HD; Taromi S; Duyster J; Börries M; Brummer T; Blazar BR; Minguet S; Turko P; Levesque MP; Becher B; Zeiser R
Mol Cancer Res; 2023 Aug; 21(8):849-864. PubMed ID: 37071397
[TBL] [Abstract][Full Text] [Related]
14. LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development.
Zhou L; Tian Y; Guo F; Yu B; Li J; Xu H; Su Z
Cancer Immunol Immunother; 2020 May; 69(5):835-846. PubMed ID: 32062693
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24.
Botchkina GI; Zuniga ES; Rowehl RH; Park R; Bhalla R; Bialkowska AB; Johnson F; Golub LM; Zhang Y; Ojima I; Shroyer KR
PLoS One; 2013; 8(9):e69884. PubMed ID: 24086245
[TBL] [Abstract][Full Text] [Related]
16. Inverse and reciprocal regulation of p53/p21 and Bmi-1 modulates vasculogenic differentiation of dental pulp stem cells.
Zhang Z; Oh M; Sasaki JI; Nör JE
Cell Death Dis; 2021 Jun; 12(7):644. PubMed ID: 34168122
[TBL] [Abstract][Full Text] [Related]
17. Humanized anti-DEspR IgG4
Gromisch CM; Tan GLA; Pasion KA; Moran AM; Gromisch MS; Grinstaff MW; Carr FJ; Herrera VLM; Ruiz-Opazo N
BMC Cancer; 2021 Apr; 21(1):407. PubMed ID: 33853558
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inhibition of Bmi-1 ablates chemoresistant cancer stem cells in adenoid cystic carcinoma.
Sahara S; Warner KA; Herzog AE; Zhang Z; Nör JE
Oral Oncol; 2023 Jul; 142():106437. PubMed ID: 37267716
[TBL] [Abstract][Full Text] [Related]
19. The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.
Nakagawa-Saito Y; Mitobe Y; Togashi K; Suzuki S; Sugai A; Takenouchi S; Nakamura K; Sonoda Y; Kitanaka C; Okada M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612758
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule correctors and stabilizers to target p53.
Fallatah MMJ; Law FV; Chow WA; Kaiser P
Trends Pharmacol Sci; 2023 May; 44(5):274-289. PubMed ID: 36964053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
